amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Clinical Trials Units for NIAID Network.

**Date:** June 10, 2013.

**Time:** 9:30 a.m. to 4:30 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817

(Telephone Conference Call).

**Contact Person:** Jay Bruce Sundstrom, Ph.D., Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 6700B Rockledge Drive, MSC–7616, Bethesda, MD 20892, 301–496–7042, sundstrom@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

**Dated:** May 10, 2013.

**David Clary,**

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–11598 Filed 5–15–13; 8:45 am]

BILLING CODE 4140–01–P

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Diabetes and Digestive and Kidney Diseases Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; DCC MAPP Network.

**Date:** June 12, 2013.

**Time:** 9:30 a.m. to 4:30 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817

(Telephone Conference Call).

**Contact Person:** Jay Bruce Sundstrom, Ph.D., Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 6700B Rockledge Drive, MSC–7616, Bethesda, MD 20892, 301–496–7042, sundstrom@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

**Dated:** May 10, 2013.

**David Clary,**

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–11600 Filed 5–15–13; 8:45 am]

BILLING CODE 4140–01–P

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Diabetes and Digestive and Kidney Diseases Notice of Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Announcement of Requirements and Registration for: “Data Rx: Prescription Drug Abuse Infographic Challenge”**

**Authority:** 15 U.S.C. 3719.

**SUMMARY:** The “Data Rx: Prescription Drug Abuse Infographic Challenge Concept” challenges the general public to create an infographic that presents information, rooted in the current research, concerning the growing trend of prescription drug abuse. The infographic should be designed to inform and educate the general public in interesting, novel, and creative ways about the dangers involved with the abuse of prescription drugs.

**DATES:**

(1) Submission Period begins May 13, 2013, 12:01 a.m., EDT.
(2) Submission Period ends June 14, 2013, 11:59 p.m., EDT.
(3) Judging will take place between June 11–July 15, 2013.
(4) Winners will be notified and prizes awarded July 30, 2013.

**FOR FURTHER INFORMATION CONTACT:** Dr. Bethany Deeds, Deputy Branch Chief, Epidemiology Research Branch, Division of Epidemiology, Services and Prevention Research, National Institute on Drug Abuse, Phone: 301–402–1935, email deedsb@nida.nih.gov.

**SUPPLEMENTARY INFORMATION:**

**Subject of Challenge Competition**

Prescription drug abuse is a growing drug problem for America. Rates of death by drug overdose have more than tripled since 1990. Most of these deaths are caused by prescription drugs. Infographics are frequently used to communicate complex information in a clear, concise and visually appealing manner to the public. Compared to other topical areas (e.g., politics, economics) the usage of infographics in health science is extremely limited, and infographics relevant to substance use and abuse rarely utilize primary data sources.

The infographic submissions in response to “Data Rx: Prescription Drug Abuse Infographic Challenge Concept” (the “Challenge”) are intended to increase awareness about the dangers of prescription drug abuse based on latest research.

This Challenge is in accordance with the National Institute on Drug Abuse (NIDA) statutory authority, described in 42 U.S.C. 2850. The general purpose of NIDA is the conduct and support of biomedical and behavioral research, health services research, research training, and health information dissemination with respect to the prevention of drug abuse and the treatment of drug abusers. Consistent with this authority, one of NIDA’s strategic goals is to prevent the initiation of drug use and the escalation to addiction in those who have already initiated use. Infographics that achieve the goals underlying this Challenge will utilize the latest research to identify the characteristics and patterns of prescription drug abuse and, accordingly, will support this strategic goal.

**Entry Materials**

Applications for this Challenge will include the following components:

1. An infographic (in .jpg format with at least a 300 dots- per-inch [dpi] resolution) that increases awareness and clearly outlines the associated dangers of prescription drug abuse.
2. A 1-page summary to accompany the infographic (4,000-character maximum). Develop a summary that explains your main points, selected approach and what conclusions the data visualization helps make. References are required and do not count towards the character limit.
3. Written consent to the eligibility rules upon or before submitting an application.

All Entry Materials must be in English. All requested information must be provided for your application to be valid.

All Entry Materials, including items 1 through 3, must be submitted to Challenge.gov which is an online challenge platform administered by the